A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

Inclusion Criteria:

1. At least 18 years old and at least of the legal age of consent in countries where itis greater than 18 years.

2. Signed and dated written informed consent in accordance with ICH-GCP and locallegislation prior to admission to the trial.

3. Male or female participants. Woman of childbearing potential (WOCBP) must be readyand able to use highly effective methods of birth control per International Councilon Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% peryear when used consistently and correctly. For men, birth control is not requiredduring the trial. A list of contraception methods meeting these criteria andinstructions on the duration of use is provided in the participant information.

4. Evidence of Chronic Kidney Disease (CKD) at risk of progression based on twoEstimated Glomerular Filtration Rate (eGFR) measurements recorded recently (i.e.within 1 year) and at the time of Visit 1, with each Estimated Glomerular FiltrationRate (eGFR) ≥20 and <60 mL/min/1.73m2, irrespective of urine albumin creatinineratio (UACR). The first of these measurements will be In Approval assessed fromhistorical local laboratory results, and the second will be determined from serumcreatinine analysed by the central laboratory at Visit 1.

5. Treatment with a clinically appropriate, stable dose of eitherAngiotensin-converting enzyme inhibitor (ACEi) or Angiotensin II Receptor Blockers (ARB) (but not both together) for ≥4 weeks before Visit 1, with no planned changesof the therapy for the duration of the trial.

Exclusion Criteria:

1. Treatment with an SGLT2i within 4 weeks before Visit 2. Treatment with a sodiumglucose co transporter 2 inhibitor (SGLT2i) should not be interrupted with theintention of enrolment into the trial.

2. Treatment with an mineralocorticoid receptor antagonist (MRA), aldosterone synthaseinhibitor (ASi), or potassium-sparing diuretic(s) within 14 days prior to Visit 1,or requiring such treatment before randomisation, or planned during the trial, basedon the judgment of the investigator. Treatment with an MRA or ASi should not beinterrupted with the intention of enrolment into the trial.

3. Blood potassium of >5.2 mmol/L at Visit 1.

4. Blood Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >3x Upperlimit of normal (ULN) at Visit 1.

5. Known severe hepatic impairment (i.e. Child Pugh class C cirrhosis).

6. On dialysis, functioning kidney transplant, or scheduled for transplant.

7. Treated with new immunosuppression therapy for new (or relapse/flare ofpre-existing) kidney disease within the last 60 days.

8. Currently treated with systemic mineralocorticoid replacement therapy (e.g.fludrocortisone).

Further exclusion criteria apply.